Connect Biopharma Holdings Limited (CNTB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Connect Biopharma Holdings Limited (CNTB) is down 20.9% since the beginning of the year. At $2 per share, CNTB is trading 41.6% below its 52-week high of $4.

Based on dividend-adjusted daily data since Sep 3, 2025, CNTB's average daily return is +0.24%, while the average monthly return is +3.25%. At this rate, an investment would double in approximately 1.8 years.

Historically, 60% of months were positive and 40% were negative. The best month was Nov 2025 with a return of +64.3%, while the worst month was Sep 2025 at -24.1%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 1 months.

On a daily basis, CNTB closed higher 47% of trading days. The best single day was Nov 14, 2025 with a return of +26.2%, while the worst single day was Sep 29, 2025 at -16.6%.

Connect Biopharma Holdings Limited has an annualized alpha of 79.94%, beta of 0.04, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 04, 2025.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (54.10%) than losses (31.31%) - typical of diversified or defensive assets.
• Beta of 0.04 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

The table below present risk-adjusted performance metrics for Connect Biopharma Holdings Limited (CNTB) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Connect Biopharma Holdings Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Connect Biopharma Holdings Limited was 41.73%, occurring on Jun 2, 2026. The portfolio has not yet recovered.

The current Connect Biopharma Holdings Limited drawdown is 39.57%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Connect Biopharma Holdings Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Connect Biopharma Holdings Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.